The oncology pharmaceutical sector is experiencing a paradigm shift as the HER2 Low Cancers Market establishes itself as a cornerstone of precision medicine advancement. This emerging therapeutic segment has captured the attention of global healthcare stakeholders, representing a convergence of scientific breakthrough and commercial opportunity that promises to redefine...